pharmaceutical compositions comprising cannabinoid cb1 receptor antagonists and potassium channel openers for the treatment of type i diabetes mellitus, obesity and related conditions

摘要

PHARMACEUTICAL COMPOSITIONS UNDERSTANDING CANBINOID RECEIVER ANTAGONISTS CB ~ 1 ~ AND POTASSIUM CHANNEL OPENERS FOR TREATMENT OF TYPE I DIABETES, OBESITY AND RELATED STATES. A novel therapeutic combination for type I diabetes and / or obesity and its concomitant and / or secondary diseases or conditions, in particular metabolic syndrome and / or syndrome X and / or type II diabetes mellitus, is described by administration. of a combination of at least one K ~ ATP ~ channel opener as a first active agent and at least one CB ~ 1 ~ cannabinoid receptor antagonist as a second active agent. The invention is also directed to said novel combination therapy in which a dual acting compound with combined K-ATP- channel opening and CB-1 antagonist properties is used. The invention also relates to novel pharmaceutical compositions comprising K-ATP channel openers and CB-1 antagonists and the use of said pharmaceutical compositions in the treatment, delayed progression, delayed onset and / or inhibition of diabetes mellitus of the type. I, and the prophylaxis and treatment of obesity as well as the prophylaxis, treatment, delayed onset and / or inhibition of its concomitant and / or secondary diseases or conditions, in particular metabolic syndrome and / or syndrome X and / or diabetes mellitus. type II in mammals and humans. The invention further relates to said novel pharmaceutical compositions comprising a double acting compound with combined KATP channel opening and CB 1 - antagonist properties.